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DURING THE PAST 16 MONTHS, all patients 
treated with renal homotransplantation at 
the Colorado General and Denver Veterans 
Administration hospitals have been ad- 
ministered heterologous antilymphocyte 
globulin intramuscularly, usually for the first 
4 postoperative months. This agent was 
used as an  adjunct to the standard im- 
munosuppressive drugs, azathioprine and 
prednisone. The preparation of the globulin 
from the serum of immunized horses (2), the 
toxicity of this agent (4, 14), and the evi- 
dence that it is of value at least early after 
human kidney transplantation (1 1, 14) have 
already been described. 
Two more questions will be examined. 
The f is t  concerns the fate of these patients 
subsequent to the discontinuance of anti- 
lymphocyte globulin. To determine this, 
the courses of 20 consecutive patients who 
received renal homografts 10 to 16 months 
ago from various blood relatives have been 
reviewed. The survivors have been followed 
up for 6 to 12 months after their last injec- 
tions of horse protein. 
Second, these and subsequent recipients 
of consanguineous kidney transplants have 
been studied to find out what effect non- 
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conformity between the antigens of donor 
and recipient lymphocytes had upon both 
early and late homograft function and upon 
the need for immunosuppressive therapy. 
This information was desirable to determine 
to what extent histoincompatibilities could 
be consistently overridden with the thera- 
peutic regimen being tested. 
Two other small groups of patients have 
been included because of their important 
bearing upon one or both of these questions. 
The first group consisted of 6 recipients of 
cadaveric homografts. The dbnor-recipient 
antigen match in each instance was poor. 
The other, a heterogenous group, consisted 
of 4 patients who were given globulin ther- 
apy for the first time long after transplanta- 
tion in an effort to halt the chronic rejection 
of their cadaveric or consanguineous homo- 
grafts. In the survivors among the latter 
patients, a follow-up period of 1 year is 
available since the last injections of globulin. 
METHODS 
In Figure 1 is shown. the way in which 
antilymphocyte globulin was used during a 
4 month period for new patients undergoing 
transplantation. The regimen was the same 
when either living or cadaveric donors were 
utilized, except tha.t preoperative treatment 
was omitted in the latter. Therapy was also 
similar in the patients who were treated 
late after transplantation. It  consisted ini- 
tially of daily injections with a dose schedule 
Reprintfrom SURGERY, Gynecology €8 Obstetrics, May, 1968, Vol. 126, 1023-1035 
Copyright, 1968, by The Franklin H. Martin Memorial Foundation 
2 Su~gey, Gynecology 6 Obstetks - May 1968 
1 256- 
1: 128- 
1:64- 
HEMAGGLUTININ 
TITER 
...++-. 116- 
1.8- 
WT 607 -+ 80.0 kgm gj 
I 
ALG a tm bT& TWEC h WLFI +{J 
II 
0 2b 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 
TIME IN DAYS 
who received antilymphocyte globulin (ALG) before and for the 
brother. The Terasaki 
started 40 days postop- 
eratively because of the high rises in the serologic titers which warned against a possible anaphylactic 
reaction. Note the insidious onset of late rejection after cessation of globulin therapy. This was 
treated bv increasing the maintenance dose of steroids. This delayed complication occurfed in onlv 
2 of the 0-1 20 patients. p I ; ,f.p*.P, I* . + * 9 M J <cn 4 
! 3 tc,! rq< , ld9 & -i. . + " - /  . t 
which was fif6gress~ve y attenuated (Fig. globulin, in a few instances ab prophylactic 
1). In vitro, the globulin agglutinated hu- immunosuppression from the day of opera- 
nlan white cells to a dilution of 1:4,000 to tion, or in some instances because the re- 
1:32,000. Individual doses were 1 to 5 
milliliters, depending upon the weight of 
the patient and the leukoagglutinin titer of 
the globulin. The protein concentration in 
the injectate was 4.6 to 10.8 grams per hun- 
dred milliliters. In 15 per cent of the pa- 
tients, the course of globulin therapy was 
prematurely stopped after 4 to 15 weeks be- 
cause of anaphylactic reactions or for other 
reasons. 
Globulin was used as an adjuvant to 
azathioprine and prednisone. The former 
drug was started the day before operation 
and continued indefinitely thereafter in 
doses judged to be nontoxic on the basis of 
frequent white blood cell determinations. 
Prednisone was given if rejection developed 
in spite of treatment with azathioprine and 
cipient had alarming increases of precipitin 
or hemagglutinin titers (Fig. 1). The ulti- 
mate quantities of prednisone administered 
generally provided a good indication of the 
difficulties in controlling rejection, since 
maintenance doses were quickly arrived at 
which were as small as possible consistent 
with retention of stable homograft function. 
In the first 20 patients with homotrans- 
plantation between blood relatives, the re- 
cipients were 7 to 47 years of age and 
weighed 12 to 75.5 kilograms. The donors 
were siblings in 13 instances, parents in 5, 
a maternal uncle in 1, and a cousin in the 
other. All donors and recipients had under- 
gone tissue typing. This analysis, performed 
by Terasaki and his associates (17), was 
based on the demonstration with a panel of 
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FIG. 2. Survival curve of the first 20 patients treated with antilymphocyte globulin (ALG) com- 
pared to that in 3 previous series of consanguineous transplantations at our institutions. Follow-up 
periods for the globulin-treated group were 10 to 16 months. The numbers in  the upper curve in- 
dicate the patients at risk for each monthly interval. 
human antisera of antigens in circulating 
lymphocytes. Compatibility, as studied with 
a given group of antisera, was said to exist 
if both donor and recipient possessed the 
same antigen, if the antigen was not present 
in either, or if it was found in the recipient 
but not in the donor. 
In these 20 patients as well as in most 
others included in the statistical analysis of 
results, the most weight was given to mis- 
matches in the named groups (Table I). 
Also considered, however, were mismatches 
between unclassified antigens. On the basis 
of the foregoing results, a summary grade of 
A to D was given according to the excellence 
of the antigen match. An A or B grade in- 
dicates that no incompatibilities existed in 
any of the 6 major groups. In all C or D 
matches, there was at least 1 such group 
incompatibility. Differentiations between A 
and B and between C and D grades were 
made on the basis of the total number of 
individual antisera mismatched from donor 
to recipient. 
The results obtained with the globulin- 
treated recipients of related homografts 
were compared extensively with those ob- 
tained in past consanguineous homotrans- 
plantations at  our institutions. The retro- 
spective control series consisted of 3 con- 
secutive groups of 32, 14, and 25 patients 
who were operated upon from November 
1962 to April 1966. By dividing the patients 
in this way, a perspective was obtained of 
tlze influence of increased experience upon 
mortality. In addition, there were differences 
in the way in which prednisone was used in 
each of the 3 groups. These variables, which 
have already been discussed at length (14), 
did not have a demonstrable effect upon 
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TABLE I.-CADAVERIC HOMOTRANSPLANTATION IN PATIENTS TREATED WITH ANTILYMPHOCYTE 
GLOBULIN 
7 2 3-4 5 6 7 Present 
(D-77, (D-Mac, (0-3, (D-9, (D-6, (0-7, creah'ninc 
P-LAI, P-LAe, VR-4A) F4D,  P-4C, VR-4B) Preformzd Summary, Survival, clearance, 
CD No. VR-7D) VR-8A) VR-6B) VR-9A) UnclassiJFed antibodies grade mos. ml./min. 
10 + - - - - - Many No C 11 15 
11 - - - - - -t Many No C- Died-3% * 
12 - + - - - - Many No D Died-3% * 
13 $. - - - - - Many Yes D 5 4/2 95 
14 + - - - - - Many No C 4% 47 
15 - - - + - + Many No D 3 55 
The antigenic incompatihilitiw between donors and recipients are shown. and the probable correspondence of the Terasaki groups to thoac of 
Dausxt (D) ,  Payne (P), and van Rood (VR) are indicated in parentheses. The unclassified antigens were also considered in deciding upon a sum- 
ma grade. 
qhese  2 patients received homografts from a common donor. Both died after 3% months within a 24 hour period. The cause of death in each 
waa multiple pulmonary embolization, a fatal complication not seen in our institutions after renal transplantation since 1964. 
CD, cadavuic. 
the results during the first postoperative 
year. Consequently, the 3 series were pooled 
for some of the statistical comparisons with 
the globulin-treated patients. In all the 
statistical analyses, drug doses were ex- 
pressed as milligrams per kilogram per day. 
Measures of renal function and circulating 
white blood cells were compiled by average 
weekly values, since these determinations 
were not available for each day. 
RESULTS 
Rec$ients of Related Homografts 
Survival. Nineteen of the first 20 patients 
are still alive with good function of the 
original transplants. In 12 of them, 12 to 16 
months have elapsed since operation; in the 
other 7 patients, the period since operation 
has been 10 to 12 months. The only death 
occurred 42 days after operation as a direct 
consequence of a surgical error. This partic- 
ular patient has been described elsewhere 
(14). 
In Figure 2, the survival curve is com- 
pared with those of each of the 3 retrospec- 
tive control series. The 5 per cent mortality 
rate in the globulin-treated patients con- 
trasted with a 28 to 31 per cent loss rate in 
each of the earlier groups during the first 12 
months. 
Histocompatibility. Five, 11, and 4 of the 
20 patients had A, B, and C antigen matches, 
respectively, with their donors. This spec- 
trum was not significantly different from 
that in retrospective series 3, in which the 
same kind of information was available for 
all patients. 
A similar distribution was found in the 80 
per cent of those in retrospective series 1 and 
2, in which typing was obtained at some 
time after transplantation. 
Immunosuppression and homograft function. For 
both the retrospective control and the test 
series, the average renal function ancl the 
doses of azathioprine and prednisone used 
to protect the homografts were determined 
for the first 4 postoperative months and for 
the 6 subsequent months. Inclusion of any 
patient in the analysis was contingent upon 
survival for 10 months, a condition that was 
met in 19 of the 20 globulin-treated patients. 
In contrast, I l ,4 ,  and 6 of the 32, 14, and 25 
patients in control groups, 1, 2, and 3, re- 
spectively, were excluded because of their 
failure to live this long, thereby eliminating 
a number of highly unfavorable patients. 
The introduction of this harsh bias did not 
obscure the favorable showing of the globu- 
lin-treated patients. 
During the time when control groups 1 to 
3 were compiIed, a progressive tendency 
existed to use smaller doses of azathioprine 
during the early postoperative period (Fig. 
3) in an effort to reduce the incidence of 
bone marrow depression. This continued 
into the globulin-treated series. The linear 
downward trend was statistically significant, 
p <.005. After 4 months, dose differences 
in the 4 series were in the same direction, 
p < .005, but less marked (Fig. 3). 
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GROUP 1 - 21 PATIENTS (21/32) 
GROUP 2 - 10 PATIENTS (10/14) 
GROUP 3 - 19 PATIENTS (19/25) 
GROUP 4 (ALG)- 19 PATIENTS (19/20) 
0 + 112 DAYS POST-TRANSPLANTATION 
113 + 294 DAYS POST-TRANSPLANTATION 
AZATHlOPRlNE I PREDNISONE CREATlNlNE CLEARANCE (mgm/kg/day) (mgm/kg/day) (ml/min) 
FIG. 3. The average azathioprine and prednisone doses per kilogram per day and the creatinine 
clearances for the first 16 postoperative weeks, shaded area, and for the subsequent 6 months, solid 
area. Shown are the retrospective control series 1,2, and 3, and the antilymphocyte globulin (ALG) 
series, group 4. Inclusion in the analysis was contingent upon survival for 294 days, a condition which 
was met with the highest regularity in the patients in the ALG group. 
The average daily dose of prednisone 
during the first 4 postoperative months was 
0.95, 1.05, and 1.28 milligrams per kilogram 
in the 3 control series. In the globulin- 
treated patients, the average value was 
0.68 milligram per kilogram, a reduction 
which was statistically significant in relation 
to groups 2 and 3, p<.025 and .005, but 
not in relation to group 1. During the en- 
suing 6 months, steroid consumption re- 
mained low in the patients of the globulin 
group (Fig. 3), a particularly encouraging 
finding since the globulin therapy had been 
stopped. 
The advantage of using smaller doses of 
the standard immunosuppressive agents in 
the globulin-treated patients was not at the 
cost of reduced homograft function. In the 
first 4 months, as well as in the subsequent 
half year, the creatinine clearances of the 
antilymphocyte globulin group compared 
favorably with the 3 control series (Fig. 3). 
The blood urea nitrogen and plasma crea- 
tinine analyses showed similar results. 
A more dynamic view of the functional 
characteristics of the homografts was ob- 
tained by pooling the creatinine clearances 
of all the retrospective control patients and 
comparing these with similar week-to-week 
data from the globulin series (Fig. 4). Dur- 
ing the first 10 postoperative months, the 
performance of the latter homografts was 
consistently better than that of the pooled 
controls, although in both groups, the clear- 
ances tended to decline slightly after some 
months. These studies showed that patients 
in the globulin series tended to retain su- 
perior function long after the heterologous 
protein therapy had been stopped. 
Whi te  cell counts. The average leukocyte 
coui~ts during the first 10 postoperative 
months were higher in the globulin-treated 
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FIG. 4. Average creatinine clearances and daily prednisone doses for the 19 of 20 globulin-treated 
patients who lived for at least 10 months after receipt of homografts from blood relatives. These 
r.esults are compared with pooled data from the 50 of 71 patients previously observed who had Lived 
for this long after similar intrafamilial hornotransplantatior1. Note the superior function and the 
smaller steroid doses of the globulin-treated patients who, because of their greater incidence of 
survival, were a less highly selected group than the included recipients in the retrospective control 
series. 
patients than in any of the retrospective con- 
trol series and probably reflected the smaller 
doses of azathioprine mentioned earlier. 
Lymphopenia was not a feature in patients 
who were receiving antilymphocyte globulin. 
Rejection. A rejection during the first 4 
postoperative months was not observed in 8 
of the 19 recipients in whom operation was 
satisfactory. In the others, rejection was 
easily reversed with an increase in pred- 
nisone dosage. A secondary rise in blood 
urea nitrogen to as high as 150 milligranls 
per hundred milliliters was seen in only 1 
of the latter patients and to as high as 100 
milligrams per hundred milliliters in 1 other. 
In  2 patients, mild late rejections were 
diagnosed after cessation of antilymphocyte 
globulin (Fig. 1). The patients were also 
managed without difficulty by an elevation 
in the maintenance dose of steroids. Their 
antigen matches were A and B, respectively. 
Itgectious comnplications. The patient with 
unrelieved uremia consequent to a tech- 
nically unsuccessful transplantation had 
pneumonitis at the time of death. In an- 
other, rneningococcemia developed 8 months 
after transplantation from which the patient 
recovered. There were 2 examples of tran- 
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FIG. 5. The average daily prednisone doses and creatinine clearances per week 
for the first 9 weeks after transplantation are shown for the 38 globulin-treated pa- 
tients, gyuped according to the histocompatibility with their donors. The A, B, 
and C ratlng indicates progressively less favorable antigenic matches. There was a 
positive correlation between the quality of the match and the level of the creatinine 
clearances as well as an inverse correlation between the excellence of the match 
and the average doses of prednisone. 
sient pneumonitis of undetermined cause 
and 1 example of herpes zoster. 
flistocompatibility, Theraky, and Function 
'I'hirty-eight instances of consanguineous 
transplantation were reviewed in which 
antilyniphocyte globulin therapy was used. 
'I'hese included the 19 recipients already 
described who have lived from 10 to 16 
months after transplantation as well as 19 
of 21 subsequently treated patients who have 
a f o l l o ~ ~  up of at  least 9 postoperative weeks. 
In the 2 excluded patients of the latter con- 
secutive series, death resulted from tech- 
nical errors after 2 and 25 days. In the in- 
cluded patients, the average daily doses of 
azathioprine and prednisone were deter- 
mined for the first 63 days as well as the 
blood urea nitrogens, creatinines, creatinine 
clearances, and white blood cell counts. In 
this way, a cross sectional view was de- 
veloped in which homograft function and 
the therapy needed to maintain this func- 
tion could be interrelated. These data were 
then pooled for the 11, 19, and 8 patients 
who had A, B, and C matches, respectively, 
with their donors. 
The average prednisone doses with A, B, 
and C matches were .64, 1, and 1.28 milli- 
grams per kilogram per day, respectively, 
whereas the creatinine clearances were 79, 
64, and 57 milliliters per minute (Fig. 5). 
The trends in both the measure of renal 
function and in the steroid doses of the 3 
groups were statistically significant, p < .05 
and .025. A similar superiority of homograft 
function in the A as opposed to the B and C 
matches was evident in the blood urea 
nitrogens and plasma creatinines. The 
white blood cell counts and azathioprine 
doses were not significantly different in the 
3 subgroups. 
Recipients qf Cadaveric Homografts 
Transplantation was performed 11, 6, 6, 
5%, 495, and 3 months aFo. No attempt was 
made at preoperative antigen matching. 
Each donor-recipient combination was later 
shown to have a high degree of incom- 
patibility (Table I). In 1 patient, preformed 
antibodies against donor tissue were de- 
tectable. The second and third patients, who 
were 6 and 45 years old, had a common 
donor. 
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Partial or complete acute tubular ne- 
crosis was evident postoperatively in 4 of 
the 6 patients, but excellent function was 
ultimately achieved in all. The 2 patients 
who received kidneys from the same donor 
both died after 103 days of multiple pul- 
monary emboli, an unusual coincidence 
since this complication has not led to a 
fatality after renal transplantation in our 
institutions since 1964. The clots originated 
from the veins of the legs in the older pa- 
tient, who had good renal function until 
just before death, and from the vena cava 
of the child. In the latter instance, anuria 
had developed suddenly, 3 days before 
death. At autopsy, the anastomosis of the 
renal vein to vena cava was found to be oc- 
cluded by the thrombus. 
The homografts were examined by K. A. 
Porter of London, England. The first of 
these 2 kidneys contained only a small 
amount of cellular infiltration which was 
principally subcapsular. No vascular or 
glomerular lesions were present. The second 
kidney had tubular and interstitial changes 
which were secondary to the venous oc- 
clusion. There was no evidence of damage 
from rejection. 
The other 4 patients still have life-sus- 
taining urine excretion by their homografts 
after 3, 434, 5%, and 11 months. In 3 pa- 
tients, function is good, but the patient who 
has survived the longest has a blood urea 
nitrogen of 60 to 80 milligrams per hundred 
milliliters and a creatinine clearance of 10 to 
20 milliliters per minute. This patient had 
excellent function until 7 weeks after cessa- 
tion of globulin therapy, when a deteriora- 
tion of function began. It was then discovered 
that he had also stopped taking azathioprine 
and prednisone. The rejection was halted, 
but not reversed, after resumption of ther- 
apy with a standard immunosuppression 
course combined with a second 3 month 
course of globulin therapy. 
Late Globulin Therapy 
The 4 patients in the group in which 
globulin administration was combined with 
reductions in prednisone dosage have pre- 
viously been described (1 1, 14). Two re- 
cipients had received cadaveric grafts 7 and 
9 months before globulin therapy was started. 
One patient who had a creatinine clearance 
of 3 to 5 milliliters per minute died before 
the 4 month course was completed. Because 
of septic complications, the other had all 
immunosuppressive therapy, including glob- 
ulin, stopped after 4 weeks of heterologous 
protein injections. He has subsequently re- 
ceived a second homograft from a related 
donor. 
The other 2 patients, who had received 
maternal homografts 5 and 11 months pre- 
viously, required 1 and 1.3 milligrams per 
kilogram per day of prednisone to maintain 
stable f~lnction. In both instances, their 
antigen matches with their donors were B. 
During the courses of globulin treatment, 
the steroid doses were drastically reduced 
without precipitating chronic rejection. 
During the subsequent year, renal function 
has remained relatively stable at its pre- 
vious subnormal levels (Fig. 6). Both pa- 
tients are now receiving a daily prednisone 
dose of .31 milligram per kilogram. 
DISCUSSION 
The first suggestion that antilymphocyte 
serum or its derivatives might eventually 
have clinical utility was made by Woodruff 
(20) in 1964. Shortly thereafter, important 
further contributions were made by Gray, 
Jeejeebhoy, Monaco, and Levey and their 
associates. All of these investigators em- 
phasized the efficacy with which serum ther- 
apy mitigated or prevented the rejection of 
skin homografts in mice or rats. Many of the 
subsequent steps which were necessary be- 
fore such foreign protein could be used in 
man were carried out in dogs in our own and 
other laboratories, as reviewed previously 
(14). 
The administration of heterologous anti- 
lymphocyte globulin in man has a number 
of disadvantages. The intramuscular injec- 
tions are painful. Moreover, there may be 
manifold signs of systemic toxicity. Fever is 
Starzl et al.: ANTILYMPHOCYTE GLOBULIN AND RENAL HOMOTRANSPLANTATION 9 
B U N  
(mgm %I 
39 +48 kgm 
AZATHIOPRINE 100- 
(mgmlday) 50 - 
0- 
PREDNISONE 50- 
(mgrnlday) A LG 
EVERY TWICE ONCE 
OTHER A A 
DAY WEEK WEEK 
1 
0 40 80 120 160 200 240 280 320 360 400 440 480 520 560 600 
TIME IN DAYS 
FIG. 6. Course of a 20 year old woman who received a course of heterologous globulin therapy 
beginning 5 months after transplantation of a homograft from her mother. Previously, reductions in 
prednisone dosage led to slow rejection. As she was treated with antilymphocyte globulin, prednisone 
was reduced to 15 milligrams per day without incident. During the year since the completion of 
globulin therapy, her function has remained relatively stable at a prednisone dose of 15 milligrams 
per day. Her antigenic match with her donor was grade B. In this instance, the multiple early post- 
operative complications made any hope for survival dependent upon rapid reduction of the steroid 
quantities. 
almost invariable. Hives, pruritis, rashes, 
and thrombocytopenia have all been docu- 
mented. Anaphylactic reactions have oc- 
curred at some time during globulin therapy 
in 20 per cent of our patients. Serologic evi- 
dence of host antibody formation against 
the horse protein can eventually be demon- 
strated in almost every patient. These toxic 
manifestations have recently been reviewed 
by Kashiwagi and his associates. 
In spite of the frequency of these side reac- 
tions, the risks imposed by repeated globulin 
injections do not appear to be excessive. 
Well over 2,000 doses have now been given 
by us to 60 patients without a drug-related 
mortality. The various complications have 
been managed without undue difficulty. 
The fear of nephrotoxicity from such ther- 
apy was largely dispelled by the results from 
homograft biopsies obtained in the first 8 
patients after a 4 month course of treatment. 
There was no evidence of either Masugi or 
serum sickness nephritis in any of the kid- 
neys (14). Nevertheless, a clear warning that 
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such a complication might occasionally oc- 
cur was given in the report by Monaco and 
his associates who observed serum sickness 
nephritis in a normal volunteer who was 
being administered rabbit gamma G glob- 
ulin. 
The benefits of antilymphocyte globulin 
seem impressive enough to outweigh its 
adverse effects. With its use, the early mor- 
tality and homograft loss rate after renal 
transplantation, at least when related donors 
were used, has been reduced to 5 per cent 
during the first postoperative year. Ap- 
parently, the improvement can be largely 
ascribed to the uniformly effective preven- 
tion of rejection without the need for high 
dose steroid therapy. This was achieved with 
a very low incidence of septic complications. 
Since the globulin therapy was confined 
to the first 4 postoperative months, the fate 
of the patients after its discontinuance has 
been a point of interest. Recently (14), it was 
speculated that any benefit conferred during 
the earlier period might outlast the interval 
of treatment, but not necessarily because of 
a continuing immunosuppressive effect. In- 
stead, the successful management of pa- 
tients during this time could permit or aid 
the evolution of the state of host-graft non- 
reactivity which often occurs weeks or 
months after transplantation (1 3). This 
poorly understood alteration in the relation 
between host and graft was termed "adapta- 
tion" by Mroodruff (21) who first demon- 
strated its development in animals. The 
consequence of the change is that patients 
often require progressively less stringent im- 
munosuppression to retain stable homograft 
function. 
To a considerable degree, this hope was 
realized in the recipients of consanguineous 
homografts. Only 2 of the 19 patients fol- 
lowed up for 6 to 10 months after their last 
globulin injections required upward ad- 
justments of steroid therapy. In the others, 
prednisone doses have either remained at 
about the same level or have been reduced 
even further. In this connection, the long 
term courses of the 2 patients still surviving 
after late globulin therapy are of particular 
interest. Both had homografts which exhib- 
ited deterioration of function whenever an 
attempt was made to reduce maintenance 
doses of prednisone. During globulin ther- 
apy, the quantities of steroids were drasti- 
cally attenuated without incident. After- 
ward, renal function has remained stable in 
both patients for longer than a year. 
These comments on the effectiveness of 
antilymphocyte globulin, for preventing 
rejection of homografts from related donors, 
have not touched on the important question 
of histocompatibility. In these patients, 
there was a spectrum of antigenic rnismatch- 
ing which has not yet reflected itself in an 
equivalent mortality distribution since re- 
cipients of badly, moderately, and well 
matched grafts have survived with equal 
frequency. Nevertheless, the price of early 
survival was higher in patients with un- 
favorable compatibility. Their difficulties 
with acute rejection and their consequent 
need for larger quantities of steroids were 
greater than in the well matched grafts. 
The f3-m correlation between the quality 
of antigenic matching and the smoothness of 
the early convalescence was a striking fea- 
ture of these patients. In the past, similar, 
but far less consistent, observations have 
been made in our institutions by Terasaki 
(12, 18) and in other centers by Terasaki 
(5, 16, 17), Rapaport, and Stickel and their 
associates. However, in every large series of 
this kind, a significant number of patients 
have had courses which were not consonant 
with the results of the compatibility exam- 
ination. One possible explanation was that 
important antigens were not being measured 
by the analyses. Another factor which has 
usually been neglected is the variable im- 
munologic reactivity which was found by 
Wilson and Kirkpatrick in victims of ure- 
mia. In candidates for renal homotrans- 
plantation, these investigators found that 
the induction of delayed or immediate 
cutaneous hypersensitivity or of humoral 
antibody formation ranged from normal to 
profoundly depressed. After transplanta- 
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tion, those patients with pre-existing intact 
immunologic capabilities tended to have 
early and vigorous rejection, whereas those 
who did not usually had late and indolent 
rejections. 
The more consistent results reported 
herein could be explained in terms of a 
partial elimination of this host variability by 
treatment with antilymphocyte globulin. 
The observations in our patients (14) and 
those of Monaco and his co-workers sup- 
port the possibility that such therapy in man 
prevents, or partially suppresses, the ap- 
pearance of delayed hypersensitivity reac- 
tions, even when these have been previously 
established. Thus, positive skin tests to 
tuberculin or other allergens become nega- 
tive within 3 or 4 days after the institution 
of globulin injections. Of the various expres- 
sions of immunologic potential, delayed 
cutaneous hypersensitivity is believed to be 
the most similar to homograft rejection. 
The foregoing considerations may ex- 
plain why, in the intrafamilial transplanta- 
tions, the addition of heterologous globulin 
therapy has made it more, rather than less, 
easy to detect the influence of antigenic 
matching upon the postoperative course. 
Nevertheless, the results have also made it 
clear that a considerable degree of his- 
toincompatibility can be consistently over- 
ridden in related patients with the therapeutic 
regimen now being used. Whether or not the 
same conclusions will apply to homotrans- 
plantation between nonrelated people re- 
mains to be seen. There are not yet enough 
patients with cadaveric homotransplants 
to permit more than speculation about this 
issue. 
Our experience is limited to 9 patients, 
the 6 renal homotransplantations herein 
reported and 3 recent orthotopic liver trans- 
plantations to be described elsewhere (1 0) 
in which survival was achieved beyond the 
first few postoperative days. In each of the 
recipients of the liver transplants, pred- 
nisone therapy was stopped or reduced to a 
dose of 5 milligrams per day or less within 
1 postoperative month, despite the presence 
of major antigenic mismatches in 2 of the 
3 patients. All 3 are still alive with good 
hepatic function from 5 weeks to 2% months 
postoperatively. 
There was a major antigenic mismatch 
in all 6 of the renal homotransplantations. 
Unfortunately, conclusions about these pa- 
tients were obscured by 2 deaths within a 
day of each other, 3% months after receipt 
of their homografts from a common donor. 
In both instances, the mortalities resulted 
from multiple pulmonary emboli which sug- 
gested some unrecognized peculiarity of the 
donor tissue. At autopsy, the kidneys had 
little, or no, evidence of rejection. In 3 of the 
other 4 patients, high steroid doses were 
used from the beginning because the poor or 
absent initial function, which resulted from 
acute tubular necrosis, made it impossible 
to know if rejection was occurring. Later, 
when prednisone was being reduced, de- 
layed rejection was noted only in the patient 
who had stopped the medications. 
In spite of this paucity of information, 
there seems little reason to doubt that anti- 
lymphocyte globulin will be of value in 
cadaveric transplantation. It  is highly un- 
likely that it will be the kind of panacea 
which will permit the indiscriminate pairing 
of all donor-recipient combinations in the 
unrelated population. For a given recipient, 
however, it should expand the pool of 
cadaveric donors from which biologically- 
acceptable organs could be obtained. 
SUMMARY 
Twenty consecutive patients received re- 
nal homografts from blood relatives 10 to 16 
months ago. All were treated with heterol- 
ogous antilymphocyte globulin in progres- 
sively diminishing quantities for the first 4 
postoperative months, and all recipients also 
received azathioprine as well as predni- 
sone. 
Nineteen or 95 per cent of these patients 
are alive with good function of their original 
homografts. In past similar instances, the 
death rate during comparable intervals was 
about 30 per cent. The improved results 
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seem attributable to an extremely efficient 
prevention or treatment of early rejection 
without the need for such high doses of 
azathioprine and especially prednisone as 
were necessary prior to the use of globulin 
therapy. Infectious complications were re- 
duced. 
The 19 surviving patients have now been 
followed up for 6 to 10 months since they 
received their last globulin injection. De- 
layed rejection occurred in only 2 patients. 
In both, this was controlled with minor 
increases in the maintenance level of ster- 
oids. Two other patients, who were treated 
with globulin for the first time 5 and 11 
months after transplantation, have sub- 
sequently had stable renal function for more 
than a year while receiving much smaller 
doses of prednisone than had previously 
been possible without precipitating rejec- 
tion. 
In the 19 surviving patients of the original 
consecutive series, as well as in 19 similarly 
treated recipients who were subsequently 
provided with consanguineous homografts, 
there was a spectrum of antigenic matches 
between the recipients and their donors. 
Until now, survival has been equivalent in 
patients with good, intermediate, or poor 
matches. However, the patients with the 
most compatible donors generally had the 
best renal function and required the smallest 
doses of prednisone. These results indicate 
that a considerable degree of histoincom- 
patibility can be consistently overridden in 
intrafamilial transplantation by the com- 
bination of these agents, but at an increased 
cost. 
There is not enough experience to date to 
know the extent to which adjuvant heterol- 
ogous globulin therapy will influence results 
after transplantation between nonrelatives. 
Six patients with cadaver homotransplants 
have been treated, all with poor donor- 
recipient antigen compatibility. Two pa- 
tients died but with little or no histologic 
evidence of homograft rejection. The others 
are alive after 3 to 11 months with poor to 
excellent function. 
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